6-K 1 a9734w.htm RESULTS OF HALEON 2023 ANNUAL GENERAL MEETING a9734w
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of April 2023
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
England and Wales
(Jurisdiction of Incorporation)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 
 
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
 
99.1
 
Press Release entitled “Results of Haleon 2023 Annual General Meeting” dated April 20, 2023
 
 
 
 
99.1
 
Haleon plc: Results of Haleon 2023 Annual General Meeting
 
20 April 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the following resolutions were decided by poll vote at the Company's 2023 Annual General Meeting ("AGM") which was held today.
 
Resolutions 20, 21, 22, 26, 27 and 28 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. Full text of the resolutions is contained in the Company's Notice of AGM, which is available at www.haleon.com.
 
Haleon plc - Poll Results by All Shareholders
 
Resolution
Votes For
For (% of shares voted)
Votes Against
Against (% of shares voted)
Total Votes Cast (excluding withheld)
% of issued share capital voted1
Votes Withheld2
1
To receive the Annual Report and Accounts
7,888,244,555
99.97
2,091,612
0.03
7,890,336,167
85.44
15,542,626
2
To approve the Directors' Remuneration Report
7,769,899,285
98.72
101,062,356
1.28
7,870,961,641
85.23
34,883,051
3
To approve the Directors' Remuneration Policy
7,728,166,817
98.19
142,531,194
1.81
7,870,698,011
85.23
35,150,085
4
To declare a final dividend
7,881,354,609
99.84
12,563,481
0.16
7,893,918,090
85.48
11,958,174
5
To re-appoint Sir Dave Lewis
7,876,931,973
99.79
16,601,260
0.21
7,893,533,233
85.48
12,312,579
6
To re-appoint Brian McNamara
7,871,084,400
99.72
22,088,009
0.28
7,893,172,409
85.47
12,708,193
7
To re-appoint Tobias Hestler
7,866,797,285
99.67
26,254,733
0.33
7,893,052,018
85.47
12,786,833
8
To re-appoint Vindi Banga
7,867,335,102
99.67
26,175,768
0.33
7,893,510,870
85.48
12,336,941
9
To re-appoint Marie-Anne Aymerich
7,890,512,208
99.96
3,112,405
0.04
7,893,624,613
85.48
12,221,032
10
To re-appoint Tracy Clarke
7,865,519,126
99.64
28,102,790
0.36
7,893,621,916
85.48
12,223,729
11
To re-appoint Dame Vivienne Cox
7,867,915,608
99.67
25,707,980
0.33
7,893,623,588
85.48
12,222,787
12
To re-appoint Asmita Dubey
7,888,796,930
99.94
4,631,311
0.06
7,893,428,241
85.48
12,314,510
13
To re-appoint Deirdre Mahlan
7,855,947,958
99.52
37,606,999
0.48
7,893,554,957
85.48
12,290,655
14
To re-appoint David Denton
7,756,457,683
98.27
136,511,465
1.73
7,892,969,148
85.47
12,872,307
15
To re-appoint Bryan Supran
7,870,491,722
99.72
22,373,713
0.28
7,892,865,435
85.47
12,981,360
16
To appoint KPMG LLP as Auditor of the Company
7,887,876,048
99.92
6,610,659
0.08
7,894,486,707
85.49
11,357,094
17
To authorise the Audit & Risk Committee to set the Auditor's remuneration
7,875,138,402
99.77
18,463,151
0.23
7,893,601,553
85.48
12,247,103
18
To authorise the Company to make political donations
7,811,060,234
99.39
48,180,724
0.61
7,859,240,958
85.11
46,594,903
19
To authorise the Directors to allot shares
7,730,625,212
97.95
161,493,695
2.05
7,892,118,907
85.46
13,723,569
20
General authority to disapply pre-emption rights
 
7,808,260,233
99.20
63,131,891
0.80
7,871,392,124
85.24
34,452,867
21
Additional authority to disapply pre-emption rights
 
7,771,569,791
98.73
99,828,862
1.27
7,871,398,653
85.24
34,442,507
22
To shorten the notice period for General Meetings
7,681,982,554
97.55
192,963,273
2.45
7,874,945,827
85.28
30,905,583
23
Approve the Performance Share Plan 2023 Rules
7,797,546,898
98.82
93,471,605
1.18
7,891,018,503
85.45
14,811,682
24
Approve the Share Value Plan 2023 Rules
7,828,310,178
99.20
62,943,305
0.80
7,891,253,483
85.45
14,570,255
25
Approve the Deferred Annual Bonus Plan 2023 Rules
7,831,723,780
99.25
58,910,350
0.75
7,890,634,130
85.45
15,186,161
26
To authorise the Company to purchase its own shares
7,878,575,931
99.82
14,281,790
0.18
7,892,857,721
85.47
12,988,792
27
To authorise the Company to make off-market purchases of its own shares from Pfizer3
4,928,538,385
99.87
6,306,129
0.13
4,934,844,514
53.44
15,940,710
28
To authorise the Company to make off-market purchases of its own shares from the GSK Shareholders4
6,688,398,038
99.91
6,123,957
0.09
6,694,521,995
72.49
16,004,606
29
Approval of waiver of Rule 9 Offer obligation5
4,768,473,630
97.47
123,562,632
2.53
4,892,036,262
52.98
58,740,625
 
1 For the purposes of section 341 of the Companies Act 2006, Haleon plc's total issued share capital with voting rights as at 6.30pm on 18 April 2023, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 9,234,573,831.
 
2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
 
3 Pfizer has agreed not to vote any of the Ordinary shares held in respect of Resolution 27.
 
4 The GSK Shareholders, as defined on page 25 of the Notice of Meeting, have agreed not to vote any of the Ordinary shares held in respect of Resolution 28.
 
5 Pfizer and any person acting in concert with Pfizer are precluded from voting on Resolution 29.
 
 
 
Haleon plc - Poll Results by Independent Shareholders
 
Resolution
Votes For
For (% of shares voted)
Votes Against
Against (% of shares voted)
Total Votes Cast (excluding withheld)
% of issued share capital voted1
Votes Withheld2
8
To re-appoint Vindi Banga
4,912,225,248
99.47
26,175,768
0.53
4,938,401,016
78.64%
12,336,941
9
To re-appoint Marie-Anne Aymerich
4,935,402,354
99.94
3,112,405
0.06
4,938,514,759
78.65%
12,221,032
10
To re-appoint Tracy Clarke
4,910,409,272
99.43
28,102,790
0.57
4,938,512,062
78.65%
12,223,729
11
To re-appoint Dame Vivienne Cox
4,912,805,754
99.48
25,707,980
0.52
4,938,513,734
78.65%
12,222,787
12
To re-appoint Asmita Dubey
4,933,687,076
99.91
4,631,311
0.09
4,938,318,387
78.64%
12,314,510
13
To re-appoint Deirdre Mahlan
4,900,838,104
99.24
37,606,999
0.76
4,938,445,103
78.64%
12,290,655
 
 
1 Percentage of votes cast by independent shareholders for Resolutions 8, 9, 10, 11, 12 and 13 appointing Independent Non-Executive Directors exclude Pfizer's 2,955,113,626 shares.
 
2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
 
As required by the Listing Rule 9.6.2R of the Financial Conduct Authority ("FCA"), copies of resolutions passed by the Company other than resolutions concerning ordinary business have been submitted to the FCA via the National Storage Mechanism and will shortly be available to the public for inspection at  https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
 
Amanda Mellor 
Company Secretary 
 
 
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com.  
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
HALEON PLC
(Registrant)
 
Dated: April 20, 2023
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary